Is [<sup>177</sup>Lu]Lu-PSMA-617 Redefining Value in mCRPC Care? A Meta-Analysis of Clinical and Economic Endpoints.

While the pooled HR for OS (HR = 0.81 [95% CI: 0.56–1.18]) confirm that it did not reach statistical significance, the time-dependent analysis based on reconstructed curves revealed that the survival benefit of [ 177 Lu]Lu-PSMA becomes more apparent after 30 months, suggesting a possible delayed effect that traditional HR-based analyses may fail to capture.

also in 111,027 other papers